Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Treating severe thrombocytopenia is a challenge in the management of systemic lupus
erythematosus. Although rheumatologists have followed some rules in real practice,there is
very few evidence to support the current treatment algorithm. The purpose of this study is to
compare the complete remission rate and partial remission rate of cyclophosphamide and
hydroxychloroquine for treating severe thrombocytopenia in Chinese SLE patients.